Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 8, 1997
Issued Date -
N/A
app pub date -
Sep 8, 1995
filing date -
Nov 27, 1992
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
As new dibekacin derivatives and new arbekacin derivatives are now provided 2'-amino-2'-deoxydibekacin, 2'-amino-5,2'-dideoxydibekacin, 2'-amino-2'-deoxyarbekacin, 2'-amino-5,2'-dideoxyarbekacin, 2'-amino-5,2'-dideoxy-5-epi-fluoroarbekacin and 2'-amino-5,2'-dideoxy-5-epi-aminoarbekacin which all exhibit high antibacterial activity against a wide variety of gram-positive and gram-negative bacteria, including resistant bacteria such as methicillin-resistant Staphylococcus aureus and which are of low toxicity to mammals and are useful as antibacterial agent for treatment of bacterial infections.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully